SABCS 2016: Medical Oncology
|
|
- Shonda Martin
- 6 years ago
- Views:
Transcription
1 1/27/17 SABCS 2016: Medical Oncology Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California San Francisco Comprehensive Cancer Center Topics What did we learn about extending adjuvant hormone therapy? Can genomic tests help predict late recurrence? Updates on hormone therapy for advanced disease What s new in HER2 positive disease? Chemotherapy topics Anthracyclines in adjuvant therapy Novel immunotoxin Tumor infiltrating lymphocytes Supportive care AI arthralgias Hair loss 1
2 Risk of Late Recurrence in ER+ Disease Early-stage (I/II) ER+ patients have good overall prognosis, but >50% of recurrences occur after Year 5 Clinical features affect recurrence risk in TransATAC Endocrine Therapy 1. EBCTCG. Lancet 2005;365: Saphner T, et al. J Clin Oncol 1996;14: Natural History of HR+ ESBC: EBCTCG 91 trials, 46,000 women with 5 years endocrine therapy for ESBC Results: risk of distant recurrence year 5-20 T1N0: 14% T2N0: 21%, T2N1-3: 29%, T2N4-9: 47% Other risk factors: tumor grade, Ki67 Implications: Clinicopathologic factors help to identify those at higher risk of recurrence after 5 years of endocrine therapy Role of extended adjuvant therapy: MA17R, NSABP B42 Role of genomics as predictive markers? Pan et al, ASCO
3 Risk of Late Recurrence in ER+ Disease Clinical and pathologic factors are prognostic 5-10y DR 5-15y DR 5-20y DR T + N T1N0 4% 9% 14% T2N0 8% 14% 21% T1N1 8% 15% 23% T1N2 15% 30% 41% T2N1 12% 20% 29% T2N2 20% 35% 47% T+N+G T1N0G1 2% 7% 11% T1N0G2 4% 9% 14% T1N0G3 5% 13% 20% 1. EBCTCG. Lancet 2005;365: Saphner T, et al. J Clin Oncol 1996;14: Pan H et al., J Clin Oncol 34, 2016 (suppl; abstr 505) Can we Improve Long-Term Outcome for HR+ ESBC? Generally, AIs for 5 years are better than tamoxifen for 5 years (EBCTCG 2015: improved all cause mortality with AIs) Sequencing tamoxifen and an AI is an alternative to 5 years of an AI Prolonging tamoxifen after tamoxifen may be beneficial, depending on individual risk Adding 5 years of an AI after 5 years of tamoxifen is beneficial 3
4 Extended Endocrine Therapy Randomized Trials: Tamoxifen followed by AI Trial Duration of Therapy (y) N Median Followup (y) Diseasefree Survival 1 Absolute Benefit Hazard Ratio (95% CI) NNT (All) 2 NNT (DR) 3 MA.17 TAM x 5y Placebo x 5y TAM x 5y AI x 5y % 94.4% 4.6% 0.58 ( ) P< NSABP B-33 TAM x 5y Placebo x 5y TAM x 5y AI x 5y % 91% 2% RR: 0.68 P= ABCSG 6A TAM x 5y Placebo x 3y TAM x 5y AI x 3y % 92.9% 4.7% 0.62 ( ) P= ATLAS TAM x 5y No further Rx TAM x 5y TAM x 5y % 78.6% 3.7% RR 0.84 ( ) p= attom TAM x 5y No further Rx TAM x 5y TAM x 5y % 72% 4% RR 0.85 ( ) P= NR MA.17R TAM x 0-5y + AI x 5y Placebo TAM x 0-5y + AI x 5y AI x 5y % 95% 4% 0.66 ( ) P= Based on disease-free survival or cumulative risk of recurrence rates as reported in the primary publications (note that the definitions of disease-free were not identical across trials) 2. Number needed to treat (NNT) based on all recurrences (local, regional, and distant) and contralateral events 3. Number needed to treat (NNT) based on distant recurrences (DR) only SABCS 2016: NSABP B-42, DATA, IDEAL 1. Goss PE et al, J Natl Cancer Inst 2005;97: Mamounas EP et al., J Clin Oncol 2008;26: Jakesz et al., J Natl Cancer Inst Dec 19;99(24): Davies C et al., Lancet ;381(9869): Gray et al., J Clin Oncol 31, 2013 (suppl; abstr 5). 6. Goss PE et al., N Engl J Med Jun 5 (Online) MA.17R: Extending Adjuvant Letrozole for 5 Years after Completing either: 5 years of AI alone OR 5 years Tamoxifen followed by 5 years AI Total of 1918 patients, median FU 6.3 years Median age 65, median time from diagnosis 10 years 46% node negative 5 year DFS: 95% LET vs 91% PLAC HR DFS 0.66, P=0.01 Letrozole Placebo DFS events: Distant: 42 vs 53 (11 events) LRR: 19 vs 30 (11 events) Bone: 28 vs 37 New CL breast cancer: 13 vs 31 Fractures: 14 vs 9% New onset osteoporosis: 11 vs 6% Contralateral new breast cancers Placebo Letrozole HR 0.42 P = Goss et al, NEJM
5 NSABP B-42: Schema Postmenopausal Pts with ER+ or PR+ Breast Cancer Stage I, II, or IIIa invasive BC at diagnosis Disease-free After 5 Years of Endocrine Therapy AI X 5 yrs or TAM X < 3 yrs à AI to Complete 5 yrs Stratification: Pathological nodal status (Negative, Positive) Prior adjuvant TAM (Yes, No) Lowest BMD T score: spine, hip, femur (>-2.0, -2.0 SD) Letrozole X 5 yrs R Placebo X 5 yrs Primary endpoint: DFS, CL BC, 2nd non-breast Ca, death from any cause 1. Mamounas EP et al. San Antonio Breast Cancer Symposium, 2016 Mamounas et al, SABCS 2016 NSABP B-42: Results 3966 pts were randomized from 9/06-1/10 Median FU for efficacy analyses: 6.9 years Compliance: Only 62.5% of P patients and 60.3% of L patients completed all 5 years of therapy 1. Mamounas EP et al. San Antonio Breast Cancer Symposium, 2016 *P-value did not reach statistical significance level of
6 NSABP B-42: Additional Analyses Cumulative Incidence of BCFI Event No difference in OS 92.3 (P) vs 91.8% (L); HR 1.15 (p=.22) Cumulative Incidence of Distant Recurrence Toxicity No difference in osteoporotic fractures 4.8 vs 5.4% (p=.27) Increase in arterial thrombotic events 3.4 vs 4% P= Mamounas EP et al. San Antonio Breast Cancer Symposium, 2016 NSABP B-42 and NCIC MA.17R Comparison of HRs for Various Endpoints Trial B-42 1 (n=3, events) MA.17R 2 (n=1, events) Endpoint Effect DFS BCFI DR OS HR 0.85* P-value HR 0.80*** 0.66** NR 0.97 P-value NR 0.83 * DFS (Recurrence + CBC + non-breast CA + deaths as first events) ** Selected as DFS in MA.17R (Recurrence + CBC) *** DFS (Recurrence + CBC + Deaths from any cause) 1. Mamounas EP et al. San Antonio Breast Cancer Symposium, Goss P. et al: NEJM
7 Phase III DATA Trial: 3 vs 6 Years of Anastrozole after 2-3 Years of Tamoxifen ü ü ü ü ü Postmenopausal at randomization ER+ and/or PR+ No sign of disease recurrence M0 breast cancer After 2-3 years adjuvant tamoxifen Stratification Nodal status ER/PR status HER2 status Tamoxifen duration 3 years anastrozole 1 mg daily 6 years anastrozole 1 mg daily Primary endpoint Adapted DFS (adfs): DFS >3 years after randomization 1912 patients randomized: minimum FU >6 years 1660 included in ITT (194 had DFS events within 3 years) 66-68% node positive, 81-81% grade II-III, 54-56% >T2 N= year adfs: 90.7% vs. 88.9% 6-year Anastrozole (N=827) 3-year Anastrozole (N=833) 5-year adfs (%) HR (95% CI) 0.79 ( ) P-value 0.07 Tjan-Heijnen et al, SABCS 2016 DATA: Additional Analyses adfs if ER+ and PR+, HER2-, pn+, Chemo+ No difference in adapted OS (4.1 yrs FU) 90.8 vs 90.4% Compliance Early termination for AEs, refusal and other 30.6% vs 17.8% N=597 5-year adfs (%) 6-year Anastrozole (N=293) 3-year Anastrozole (N=286) P value (HR, 95% CI) 0.01 (0.58; ) Toxicity: no real difference Grade, years year Anastrozole 3-year Anastrozole (N=827) (N=833) Any Grade 3 Any Grade 3 Arthralgia / myalgia 57.6% 8.0% 51.9% 5.5% Bone fractures 9.8% 2.1% 7.4% 2.5% Osteopenia / osteoporosis 20.9% 1.3% 16.5% 0.8% Cardiovascular incl. arrhythmia 13.4% 3.5% 12.9% 3.4% 7
8 Phase III IDEAL Trial: Optimal Duration of Letrozole after 5 Years Tamoxifen Aromatase Inhibitor (AI) R Letrozole Primary endpoint: DFS 1824 patients Median FU 6.5 yrs 74% N+ Tamoxifen AI Letrozole 5 years adjuvant therapy Postmenopausal ER/PR positive No recurrence / 2 nd malignancy 0-2 years 2.5 or 5 years extended therapy Stratification: Prior endocrine therapy, time after endocrine therapy, nodal status, adjuvant chemotherapy No difference in DFS Primary: 88.4 (2.5 yr) vs 87.9% (5 yr); HR 0.96 Subgroup analysis Suggested benefit in node positive, but 2.5 yrs >5 for N neg, low grade No difference in OS 2.5 vs 5 years Primary: 93.5 vs 92.6% No diference in DMFI 6.1 vs 7.1% van de Velde (Blok) et al, SABCS 2016 Additional Analyses Toxicity 2.5 years 5 years N pa,ents 640 (70%) 643 (70%) N AE ( 16%) % CTC grade % 9.7% HR: 0.37 ( ) P-value nd BC 5 years 2.5y: 1.9% 5y: 0.9% Arthalgia: 14% Hot flashes:12% Osteoporosis: 10% Compliance: early stopping without PD 2.5 years 5 years Early stop (n) 241 (27%) 385 (~42%) Symptoms/AE + refusal 179 (74%) 254 (66%) 8
9 Can Genomic Tests Help to Predict Late Recurrence Risk? Comparison of Prognostic Signatures for Breast Cancer Recurrence in TransATAC (n=818) Signature Information included Clinical Treatment Score (CTS) Nodal status, grade, tumour size, age, treatment Immunohistochemical markers (IHC4) ER, PgR, Ki67, HER2 Oncotype Recurrence Score (RS) 21 genes (oestrogen, proliferation, invasion, HER2 genes) Breast Cancer Index (BCI) H/I and 5 proliferation genes (Molecular Grade Index) Prosigna (ROR) EndoPredict (EPclin) 46 genes, proliferation score, tumour size (EU cut-offs from transatac for N- and N+) 12 genes (proliferation, differentiation, oestrogen); nodal status and tumour size 5 years tam or AI, NO chemo, primary endpoint DR Sestak et al, SABCS
10 N0 N+ Late Distant Relapse by Assay, transatac (yr 5 to10) IHC4 BCI RS ROR EPclin IHC4 BCI RS ROR EPclin CTS Sestak SABCS Likelihood Ratio χ 2 CTS Likelihood Ratio χ 2 % Improvement 20.0% 67.5% 11.4% 111.0% 62.0% % Improvement 7.5% 11.3% 6.9% 25.6% 27.5% Distant recurrence free (%) Distant recurrence free (%) BCI RS ROR EPclin RS ROR EPclin Follow-up time [years] DR risk % 2.5% 14.4% 15.9% 1.4% 10.0% 23.2% 4.3% 14.6% Follow-up time [years] DR risk % BCI Patients % in risk groups 63.6% patients 23.6% patients 12.9% patients 4.8% 65.6% patients 9.6% 25.1% patients 16.1% 9.4% patients 14.3% 19.7% 36.5% 0% 13.0% 25.0% 3.3% 23.6% 54.6% patients 30.8% patients 14.6% patients 73.5% patients 26.5% patients Patients % in risk groups 51.7% patients 32.4% patients 15.9% patients 17.9% 61.0% patients 19.5% 30.2% patients 27.5% 8.8% patients 8.2% patients 28.0% patients 63.7% patients 22.0% patients 78.0% patients Clinicopathologic Factors are Critical with Genomic Testing to Assess Late Recurrence Risk A new BCI Prognostic algorithm was developed to assess risk of recurrence in HR+ patients with 1-3 positive nodes (BCIN+) New model developed using TransATAC N1 patients (n=209) Independent validation in retrospective case series (N=402) BCIN+ categorized 20% of patients as Low Risk 1.3% risk of recurrence over 15 years Distant Recurrence (%) All Patients (0-15 Yr) Low High HR: ( ) P < % 1.3% Years No. at risk Low High Distant Recurrence (%) HR: NA P < HER2- (0-15 Yr) Low High 29.1% 0% Years No. at risk Low High Distant Recurrence (%) All Patients (5-15 Yr) Low High HR: ( ) P = % 1.3% Years No. at risk Low High Distant Recurrence (%) HR: NA P = HER2- (5-15 Yr) Low High Years No. at risk Low High Zhang et al. ASCO % 0% 10
11 Summary and Analysis Variation in study designs makes comparisons difficult Relatively low risk of recurrence at median FU Careful assessment of potential risks and benefits is required before recommending extended AI Rx Patients randomized on extended duration trials Are unique as tolerated 2-5 years of AI therapy Early discontinuation for toxicity frequent; impacts ability to analyze impact of therapy Patients at very high risk for late recurrence should be considered for extended duration hormone therapy Optimal duration unknown; AI or tamoxifen reasonable, awareness of toxicities critical Genomic tests to assess risk and predict benefit are critical Stay tuned to further analyses from NAABP B-42 Role of targeted agents, CDKi and others, remains to be determined Expected Survival Impacts Potential Benefits of Extended Adjuvant Therapy Any (T1/2, N0-9) ER+ disease, adjusted for T and N status Age after 5 years ET Distant recurrence: Adjusted RR (95% CI) Survival, years 5-20, if no breast cancer death < ( ) 97% ( ) 93% ( ) 91% % ( ) 48% Pan et al, ASCO
12 Effect of Body Mass Index on Recurrence in ATAC Trial BWEL Study Schema 3136 participants Key Eligibility: Stage II-III breast cancer HER-2 - BMI 27 kg/m2 R A N D O M I Z E 2-year telephone-based weight loss intervention + Health education Health Education Alone Conducted through NCTN/NCORP Activation date: August 1, 2016 J Clin Oncol 2010; 28; Study design Recent Phase III First-Line Studies in HR+ MBC Paloma-2 Finn et al, NEJM 2016 Letrozole/Pla vs Letrozole/Palbociclib No. of pts 666 No progression on AIs PFS 14.5 vs 24.8 mo HR 0.58 ( ) p< Monaleesa-2 Hortobagyi et al, NEJM 2016 Letrozole/Pla vs Letrozole/Ribociclib 668 No progression on AIs 14.7 vs NR (19.9-NR) mo HR ( ); p= All oral Yes Yes No Subset difference Falcon Robertson et al, Lancet 2016 Anastrozole/Pla vs Fulvestrant/Pla 462 No prior hormone therapy 13.8 vs 16.6 mo. HR ( ); p= No No 13.8 v 22.3 mo in n= 218 (47%) without visceral disease No difference in those with visceral disease 12
13 Comparison of Trials in Patients with Progression on Prior NSAI Study design PALOMA 3 Turner et al, NEJM 2015, SABCS 2016 Fulvestrant/pla vs fulvestrant/palbociclib BOLERO 2 Baselga et al, NEJM 2012 Yardley et al, Adv Ther 2013 Exemestane/pla vs exemestane/eve Patient # PFS (mo) p value (HR) 4.6 vs 11.2 p<.0001, (HR 0.5) 3.2 vs 7.8 (inv) 4.1 vs 11 (central) p<.0001 (HR.38) PreCOG Kornblum et al, SABCS 2016 Fulvestrant/pla vs fulvestrant/eve 5.1 vs 10.4 p=.02 (HR.6) Abemaciclib Single agent ORR 19.7% (Dickler et al, ASCO 2016) Crosses BBB, diarrhea > neutropenia NeoMONARCH (Hurvitz et al, SABCS 2016) 223 pts, biomarker trial Complete cell cycle arrest at 2 wks Induces immune infiltrate Response Rate (%) Complete Cell Cycle Arrest (3.4, 20.2) OR = p<0.001 b (4.7, 27.4) p<0.001 b Responders : (Ki67 index <2.7% at 2 weeks) BELLE-3: Buparlisib/Fulvestrant after mtori PFS by PIK3CA Status Probability of PFS, % 100 Tissue (mutant) Buparlisib + Placebo + Fulvestrant Fulvestrant Primary tumor Median PFS, Median PFS, tissue (PCR) months (95% CI) ( ) ( ) months (95% CI) ( ) ( ) N=321 HR (95% CI) 0.39 ( ); p<0.001 HR (95% CI) 0.83 ( ); p= PIK3CA mutant: Significant hepatic toxicity, hyperglycemia, rash, 34% depression/anxiety Future 0 development of pan PI3K 0 inhibitors not feasible but biomarker data intriguing Alpha 100 specific PI3K hold signficiant 100 Buparlisib + Placebo + ctdna (mutant) Buparlisib + Placebo + promise ctdna (WT) Fulvestrant Fulvestrant Fulvestrant Fulvestrant Alpelsib 80 (Solar-1) 80 Median PFS, Median PFS, months (95% CI) ( ) ( ) months (95% CI) ( ) ( ) Pictilisib 60 (Sandpiper) 60 HR (95% CI) 0.46 ( ); p<0.001 HR (95% CI) 0.73 ( ); p=0.026 Triplet 40 therapy of interest (hormone 40 rx, PI3Ki, CDKi) ctdna samples at study entry (BEAMing) N=348 PIK3CA mutant: 39% Probability of PFS, % 20 Mutant Wild-type Tissue (WT) Buparlisib + Placebo + Fulvestrant Fulvestrant 0 0 PCR, polymerase chain reaction; WT, wild-type. p-values are one-sided Time, Months Time, Months DiLeo et al, SABCS
14 Optimal Sequencing of Endocrine Therapy in ER+ MBC 1 st line approach Delay Start of Chemotherapy OS 2 nd line approach A. Conventional endocrine mono-therapy B. Optimally selected endocrine mono-therapy AI alone 8 14 months Fulvestrant months Exemestane 3 4 months (ie. endo Rx naïve, non-visceral mets, biomarker) AI or fulvestrant + everolimus months Fulvestrant + CDK4/6 I 11.2 months AI + CDK4/6 i 7 9 months? AI + everolimus 7 9 months? A B C 2 nd line post Fulvestrant: responsive to 2 nd line combinations? C. Combination Endocrine Strategy AI + CDK4/6 i 24 months Fulvestrant months? PI3K inhibitors? AI + everolimus 7 11 months? 2 nd Line post CDK 4/6 inhibitors: still endocrine responsive and to what therapy? Cumulative Median Progression-Free Survival (PFS) in months Overall Survival (OS) Adapted from Johnston, SABCS 2016 Symptom Control is a Critical Issue: Managing Arthralgias Exercise, yoga, acupressure, acupuncture. NSAIDS Regular check in with clinic/providers Duloxetine HCL (SWOG S1202: Henry et al, SABCS 2016) SNRI, FDA approved for chronic pain disorders Post menopausal, stage I-III, AI for 3 weeks 36 months Average MS pain of >4/10 on AI Average joint pain decrease in both arms The difference between the 2 arms started at 2 weeks Difference in average joint pain 0.82 (p=0.002) Side effects manageable Percentage of pa6ents with 2 point improvement 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 54% 44% 69% 69% 49% Duloxe6ne Placebo 60% 60% 59% 2 weeks 6 weeks 12 weeks 24 weeks 14
15 Preventing Chemotherapy Induced Alopecia (in press, JAMA 2017) SCALP (Paxman, Nangia et al, SABCS 2016) 140 pts with stage I-II breast cancer 1/3 anthracycline. 2/3 taxane Stopped at interim analysis Dignicap (Rugo et al, ASCO 2015) Taxane based chemotherapy Success by regimen TC (63.2%), Tca (83.3%), paclitaxel (100%) Dean Score N (%) DigniCap N = 101 Success/ Failure % (N) 0 (no hair loss) 1 (>0 and up to 25% hair loss) 5 (5%) 31 (30.7%) Success: 66.3%* (71, 2 (>25% and up to 50% 31 95% CI, hair loss) (30.7%) 75.4%) 3 (>50% and up to 75% 19 hair loss) (18.8%) Failure: 4 (> 75% hair loss) % (34) (14.9%) Control N = 16 Success/ N (%) Failure % (N) 0 (0.0%) 0 (0.0%) 0 (0.0%) Success: 0.0% (0) 1 (6.3%) Failure: 100.0% 15 (16) (93.8%) *p-value for comparing DigniCap to control P<0.001 from Fisher s exact test HER2+/HR+ Disease NSABP B-52 (n=309) Neoadjuvant therapy HER2+/HR+ TCHP x 6 vs TCHP + estrogen deprivation No difference in pcr 41 vs 46% No difference in pre- or post-menop women No reason to add ET to chemo + HER2-targed rx in HER2+ disease PERTAIN (n=258) First-line ph II trial in HER2+/HR+ MBC TP/AI vs T/AI Allowed chemotherapy first PFS: 18.9 vs 15.8 mo HR 0.65, p.007 ORR: 63 vs 56%, NS Pertuzumab works, reasonable to continue when switching from THP to T/AI Rimawi et al, SABCS 2016 Rimawi et al presented by Arpino), SABCS
16 N=150 HER2+ Breast Cancer stage I-IIIA Baseline PAM50 Predicting Benefit from HER2 Targeted Therapy: PAMELA Trial PAMELA trial schema 18 weeks Trastuzumab 6 mg/kg every 3 weeks Lapa6nib 1000 mg/day + Letrozole or Tamoxifen if HR+ Week 2 Week 6 PAM50 Ultrasound PD* Trastuzumab 6 mg/kg every 3 weeks Lapa6nib 750 mg/day Paclitaxel 80 mg/m 2 weekly x 12 *, defined as any increase in tumor size. This presentation is the intellectual property of the author/presenter. Contact them at alprat@clinic.cat for permission to reprint and/or distribute S U R G E R Y Adjuvant systemic treatment was at the discremon of the treamng physician Intrinsic subtype distribution at baseline LumA LumB HER2-E Basal-like Normal-like Intrinsic subtypes: heterogeneous in HER2+ disease (n=151) Vary by ER status HER2-E have greater pathway activation, better response to combination neoadjuvant therapy Do these patients need less? pcr rate 100% 80% 60% 40% 20% 0% 40.6% =30.6% 10.0% pcr breast pcr All samples N= % 2% 66.9% 34.7% 14.6% =24.7% 10.6% 10.0% pcr breast/axilla 100% 80% 60% 40% 20% 0% HR+ samples N=77 LumA LumB HER2-E 49.3% 1.3% Basal-like Normal-like 40.6% HER2-E (n=101) 28.6% 20.8% 0% LumA (n=22) 12.5% LumB (n=16) 2.7% LumA 12.2% LumB HR-neg samples N=74 HER2-E Basal-like Normal-like pcr breast 11.1% 85.1% 66.7% Basal-like Normal-like (n=9) (n=3) Pratt et al, SABCS 2016 Chemotherapy for TNBC Update of the TNT trial (Tutt et al, SABCS 2016) TNBC, first line therapy, carboplatin vs docetaxel Carboplatin superior for ORR in gbrca BRCAness did not predict benefit from carboplatin (docetaxel better) TnAcity (Yardley et al, SABCS 2016) First line therapy for TNBC Nab-paclitaxel (125 mg/m2)/carbo AUC 2 less toxic nab/ca (n=64) nab/gem (n=61) Gem/Ca (n=66) ORR 72% 39% 44% mpfs 7.4 mo 5.4 mo (HR 0.6, , p.02) 6.0 mo (HR 0.61, , p.03) 16
17 Novel Agents: Sacituzumab Govitecan (IMMU-132) Anti-Trop-2 Antibody Drug Conjugate Phase I expansion in TNBC 10mg/kg days 1 and 8 q 21 Median number of prior therapies 5 (2-12) 85 evaluable patients ORR: 29.4% (25/85) 2 CR, 26 PR, 33 SD ; CBR 44% Median DOR 10.8 mo PFS 6 mo. Toxicity (>gr3) 39% neutropenia, 7% FN 10% emesis 13% diarrhea 10% hypophosphatemia Antibody-drug conjugate targeting Trop-2 Antigen present in many epithelial cancers, including TNBC Delivers SN-38, a topoisomerase I inhibitor Bardia et al, SABCS 2016 Role of Anthracyclines in ESBC: DBCG 07 DC x 6 vs EC x 3 D x 3 in TOP2A Normal BC Selection Criteria Invasive breast cancer Comorbidity index < 3 High risk 1. Node positive 2. High risk node neg. Young age ER negative HER2+ T size High grade Altered TOP2A TOP2A/Cen17 ratio < 0.8 or TOP2A tested 16% (835) altered TOP2A Normal TOP2A TOP2A/Cen17 ratio x EC 3 x Docetaxel 90/600 mg/m mg/m 2 3 x EC 90/600 mg/m 2 6 x DC 75/600 mg/m 2 N=835 3 x Docetaxel 100 mg/m 2 N=994 N=1006 ABC trials (Blum ASCO 2016) Benefit of anthracyclines greatest in higher risk disease (TN, node positive) Is removal of TOP2A mutant cancers important? (Anthracycline sensitive?) Seems reasonable to use DC in lower risk tumors still requiring adjuvant chemotherapy but do those patients need chemorx? EC/D not superior to DC in TOP2A normal BC and more toxic Ejlertson et al, SABCS
18 Tumor Infiltrating Lymphocytes Metaanalysis of 3771 patients (GBG) High TILS are more frequent in TNBC (30%)>HER2 (19%)>luminal tumors (13%) TILS are linked to increased pcr rates in all subtypes High TILS associated with OS for TNBC and HER2; low TILS associated with OS for luminal TILS in the Cleopatra trial More common in ER neg, and Asian>White>AA Lower TILS in metastatic tumor than primary, and in all visceral sites but lung OS associated with mean TIL level Linear impact, each 10% increase in TILS=11% reduction in risk of death. Denkert et al, SABCS 2016; Luen et al, SABCS 2016 UCSF TBCRC Multi-Center Immunotherapy BCRF Funded Trial TNBC OX-40 and 4-1BB antibodies are immune agonists Binimetinib :MEK 1/2 inhibitor Avelumab: PD-L1 inhibitor 18
19 1/27/17 Raising the Bar in the Treatment of Breast Cancer Thank you! 19
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationHormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & Chair NR Committee
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationOVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER
OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER Aleix Prat, MD PhD Medical Oncology Department Hospital Clínic of Barcelona University of Barcelona esmo.org Disclosures Advisory role for
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationTriple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationThe Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer
The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer Erin Roesch, MD, and Claudine Isaacs, MD Abstract Endocrine therapy in the adjuvant setting
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationHighlights. Padova,
Highlights P Pronzato Padova, 17.11.2012 Last 12 Months Main Meetings SABCS 2011 (San Antonio) EBCC 8 2012 (Wien) ASCO 2012 (Chicago) ESMO/ECCO 2012 (Wien) The Medical Oncology Job Risk Manager Strategy
More informationSession thématisée Les Innovations diagnostiques en cancérologie
10 èmes Journées Scientifiques du Cancéropôle Nord-Ouest 10-12 mai 2017, Deauville Session thématisée Les Innovations diagnostiques en cancérologie Les signatures multigéniques pronostiques dans le cancer
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationSession Breast Cancer. Alessandra Fabi Il punto di vista dell esperto
Session Breast Cancer Alessandra Fabi Il punto di vista dell esperto Roma 6-7.10.2017 The Importance of Understanding What Disease to Treat Cejalvo et al, Cancer Res 2017 Skyline Chaging at evolution of
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationAggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationOptimization of Hormone Treatment: New Alternative Sequences
Optimization of Hormone Treatment: New Alternative Sequences ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Review of triple negative breast cancer and new agents GASCO Review of SABCS 2014 January 10 th 2015, Atlanta, GA Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationAdvances in the Diagnosis and Treatment of Breast Cancer. Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD
Advances in the Diagnosis and Treatment of Breast Cancer Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD Disclosures Genomic Health: Speaker and Consultant AstraZeneca:
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More information